<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02501109</url>
  </required_header>
  <id_info>
    <org_study_id>CMG-ARI-140052</org_study_id>
    <nct_id>NCT02501109</nct_id>
  </id_info>
  <brief_title>Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film vs Abilify® 10 mg Tablet in Healthy Volunteers</brief_title>
  <official_title>A Single-dose, Randomized, Three-period, Crossover Comparative Bioavailability Study of a Novel Formulation of Aripiprazole 10 mg Oral Soluble Film vs the Marketed Formulation Abilify® 10 mg Tablet in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CMG Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CMG Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the rate and extent of absorption of Aripiprazole&#xD;
      Oral Soluble Film 10 mg (Test) versus Abilify® 10 mg tablet (Reference) in healthy male&#xD;
      volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a single centre, bioavailability, open-label, randomized, single-dose,&#xD;
      3-period, 6-sequence, crossover study under fasting conditions. Each volunteer will be given&#xD;
      a single dose of the Test formulation in two study periods (with and without water), and a&#xD;
      single dose of the Reference formulation (with water) in the other study period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate extent of absorption of aripiprazole OSF 10mg versus Abilify ® 10mg tablet</measure>
    <time_frame>Baseline to 28 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days with water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days without water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gruop C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive the reference drug Abilify tab. 10mg orally a single of dose within 28 days with water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Healthy volunteers will receive Aripiprazole Oral Soluble Fim(OSF) 10mg orally a single of dose within 28 days</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Gruop C</arm_group_label>
    <other_name>Abilify® 10 mg tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, moderate smoker (no more than 9 cigarettes daily) or non-smoker, ≥45&#xD;
             and ≤65 years of age, with BMI &gt; 18.5 and &lt; 30.0 kg/m2 and body weight 50.0 kg for&#xD;
             males and 45.0 kg for females.&#xD;
&#xD;
          2. Healthy as defined by:&#xD;
&#xD;
          3. Females of childbearing potential who are sexually active with a male partner must be&#xD;
             willing to use one of the following acceptable contraceptive method throughout the&#xD;
             study and for 42 days after the last study drug administration:&#xD;
&#xD;
          4. Capable of consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any clinically significant abnormality or abnormal laboratory test results found&#xD;
             during medical screening or positive test for hepatitis B, hepatitis C, or HIV found&#xD;
             during medical screening.&#xD;
&#xD;
          2. Positive urine drug screen at screening.&#xD;
&#xD;
          3. History of allergic reactions to aripiprazole, dimenhydrinate, benztropine,&#xD;
             diphenhydramine or other related drugs.&#xD;
&#xD;
          4. Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days&#xD;
             prior to the first study drug administration.&#xD;
&#xD;
          5. Positive pregnancy test at screening.&#xD;
&#xD;
          6. Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          7. Clinically significant electrocardiogram (ECG) abnormalities or vital sign&#xD;
             abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood&#xD;
             pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm),&#xD;
             decrease in systolic blood pressure of 20 mmHg or higher, or decrease in diastolic&#xD;
             blood pressure of 10 mmHg or higher within 2 to 3 minutes after passing from a supine&#xD;
             to a standing position, at screening.&#xD;
&#xD;
          8. History of significant alcohol abuse within one year prior to screening or regular use&#xD;
             of alcohol within six months prior to the screening visit (more than fourteen units of&#xD;
             alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).&#xD;
&#xD;
          9. History of significant drug abuse within one year prior to screening or use of soft&#xD;
             drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs&#xD;
             (such as cocaine, phencyclidine (PCP), and crack) within 1 year prior to screening.&#xD;
&#xD;
         10. Use of aripiprazole for a medical condition or in the context of another clinical&#xD;
             trial within a period of 42 days prior to the first dosing.&#xD;
&#xD;
         11. Participation in a clinical trial involving the administration of an investigational&#xD;
             or marketed drug within 30 days (90 days for biologics) prior to the first dosing or&#xD;
             concomitant participation in an investigational study involving no drug&#xD;
             administration.&#xD;
&#xD;
         12. Use of medication other than topical products without significant systemic absorption&#xD;
             and hormonal contraceptives:&#xD;
&#xD;
               -  prescription medication within 14 days prior to the first dosing;&#xD;
&#xD;
               -  over-the-counter products including natural health products (e.g. food&#xD;
                  supplements and herbal supplements) within 7 days prior to the first dosing, with&#xD;
                  the exception of the occasional use of acetaminophen (up to 2 g daily);&#xD;
&#xD;
               -  a depot injection or an implant of any drug (other than hormonal contraceptives)&#xD;
                  within 3 months prior to the first dosing.&#xD;
&#xD;
         13. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding&#xD;
             volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than&#xD;
             499 mL within 56 days prior to the first dosing.&#xD;
&#xD;
         14. Hemoglobin &lt;128 g/L (males) and &lt;115 g/L (females) and hematocrit &lt;0.37 L/L (males)&#xD;
             and &lt;0.32 L/L (females) at screening.&#xD;
&#xD;
         15. Breast-feeding subject.&#xD;
&#xD;
         16. HAM-D-7 scale score above 3 at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung Jo Kim, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Development Div.</affiliation>
  </overall_official>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>June 4, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <last_update_submitted>March 23, 2016</last_update_submitted>
  <last_update_submitted_qc>March 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aripiprazole</keyword>
  <keyword>Oral Soluble Film</keyword>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

